Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.48797/sl.2023.51 |
Resumo: | Background: Enterococcus lactis (Elts) [former Enterococcus faecium (Efm) clade-B] has been greatly associated with human colonization, but its epidemiology is unknown since this reclassification [1]. We aimed to assess the contemporary faecal carriage of enterococci species among healthy-humans (HH) in Portugal and get novel insights about Efm/Elts differences. Methods: Fifty-one faecal samples (29-women/22-men;18-85/~45-years) from HH in Northern Portugal (February-July 2022) were processed by enrichment/selection steps with/without ampicillin, vancomycin or linezolid. Efm, Elts and other species were identified by PCR [2, 3] and antibiotic-susceptibility by disk-diffusion/broth-microdilution (EUCAST/CLSI). Representatives/sample (n=40) were characterized by Whole-Genome-Sequencing/CGE-tools, including a homemade bacteriocins(bac) database. Qualitative bacteriocin production/sensitivity was performed in sequenced Efm/Elts and selected clinical VREfm (vancomycin-resistant-Efm) and Elts (all-against-all) using the soft-agar-overlay technique. Results: All samples carried Enterococcus (n=337), with most containing Elts-73% (p<0.05) and/or E.faecalis (Efs)-61% and variable occurrence for Efm-45%, E.hirae-16%, and/or other species (<2%). Samples (24% multidrug-resistant) included isolates resistant to erythromycin [73%;erm(B)/msr(C)], tetracycline [63%;tet(M)/tet(L)], high-level-streptomycin (22%;ant(6)-Ia/str), chloramphenicol (12%;cat/fexA/fexB/optrA/poxtA), quinupristin-dalfopristin (12%), high-level-gentamycin [4%;aac(6’)-Ie-aph(2’’)-Ia] and linezolid (4%-optrA/poxtA;MIC50/MIC90 4-mg/L). Acquired linezolid-resistance genes were detected in two samples: optrA (one E. thailandicus; MIC=8-mg/L) and optrA+poxtA (ST128-Efm; MIC=8-16-mg/L). Typical bacteriocins and plasmids from clinical Efm/Efs were scarce. Elts (2-5 bac; 100%-bac-genes+) and Efm (0-9; 71%-bac+) shared bacteriocins (e.g.,entP/entQ) contrasting with others exclusive of Efs (0-2;22%-bac+). No isolate could inhibit all or be inhibited by all, but the ones with more bacteriocins were less inhibited. Most Efm/Elts showed no activity against each other but ~30%/each inhibited most strains tested, including VREfm. Conclusions: Elts is one predominant enterococci gut species that would be misidentified as Efm without an accurate Efm/Elts distinction. Elts co-exist with Efm in the intestine, but specific Efm/Elts inhibiting most strains tested may contribute to microbiota restoration after antibiotic treatments. Linezolid-resistance genes finding is worrisome, suggesting an environmental/food-chain role in this acquisition since they were not described in enterococci from Portuguese hospitals before. |
id |
RCAP_8d9ffc9be8656e401cc96c66c365f343 |
---|---|
oai_identifier_str |
oai:publicacoes.cespu.pt:article/51 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic speciesSelected Oral CommunicationBackground: Enterococcus lactis (Elts) [former Enterococcus faecium (Efm) clade-B] has been greatly associated with human colonization, but its epidemiology is unknown since this reclassification [1]. We aimed to assess the contemporary faecal carriage of enterococci species among healthy-humans (HH) in Portugal and get novel insights about Efm/Elts differences. Methods: Fifty-one faecal samples (29-women/22-men;18-85/~45-years) from HH in Northern Portugal (February-July 2022) were processed by enrichment/selection steps with/without ampicillin, vancomycin or linezolid. Efm, Elts and other species were identified by PCR [2, 3] and antibiotic-susceptibility by disk-diffusion/broth-microdilution (EUCAST/CLSI). Representatives/sample (n=40) were characterized by Whole-Genome-Sequencing/CGE-tools, including a homemade bacteriocins(bac) database. Qualitative bacteriocin production/sensitivity was performed in sequenced Efm/Elts and selected clinical VREfm (vancomycin-resistant-Efm) and Elts (all-against-all) using the soft-agar-overlay technique. Results: All samples carried Enterococcus (n=337), with most containing Elts-73% (p<0.05) and/or E.faecalis (Efs)-61% and variable occurrence for Efm-45%, E.hirae-16%, and/or other species (<2%). Samples (24% multidrug-resistant) included isolates resistant to erythromycin [73%;erm(B)/msr(C)], tetracycline [63%;tet(M)/tet(L)], high-level-streptomycin (22%;ant(6)-Ia/str), chloramphenicol (12%;cat/fexA/fexB/optrA/poxtA), quinupristin-dalfopristin (12%), high-level-gentamycin [4%;aac(6’)-Ie-aph(2’’)-Ia] and linezolid (4%-optrA/poxtA;MIC50/MIC90 4-mg/L). Acquired linezolid-resistance genes were detected in two samples: optrA (one E. thailandicus; MIC=8-mg/L) and optrA+poxtA (ST128-Efm; MIC=8-16-mg/L). Typical bacteriocins and plasmids from clinical Efm/Efs were scarce. Elts (2-5 bac; 100%-bac-genes+) and Efm (0-9; 71%-bac+) shared bacteriocins (e.g.,entP/entQ) contrasting with others exclusive of Efs (0-2;22%-bac+). No isolate could inhibit all or be inhibited by all, but the ones with more bacteriocins were less inhibited. Most Efm/Elts showed no activity against each other but ~30%/each inhibited most strains tested, including VREfm. Conclusions: Elts is one predominant enterococci gut species that would be misidentified as Efm without an accurate Efm/Elts distinction. Elts co-exist with Efm in the intestine, but specific Efm/Elts inhibiting most strains tested may contribute to microbiota restoration after antibiotic treatments. Linezolid-resistance genes finding is worrisome, suggesting an environmental/food-chain role in this acquisition since they were not described in enterococci from Portuguese hospitals before.IUCS-CESPU Publishing2023-04-21info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.48797/sl.2023.51https://doi.org/10.48797/sl.2023.51Scientific Letters; Vol. 1 No. Sup 1 (2023)2795-5117reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://publicacoes.cespu.pt/index.php/sl/article/view/51https://publicacoes.cespu.pt/index.php/sl/article/view/51/104Copyright (c) 2023 A. C. Almeida-Santos, B. Duarte, M. J. Teixeira, A. P. Tedim, C. Novais, L. Peixe, A. R. Freitasinfo:eu-repo/semantics/openAccessAlmeida-Santos, A. C.Duarte, B.Teixeira, M. J.Tedim, A. P.Novais, C.Peixe, L.Freitas, A. R.2023-04-29T08:46:01Zoai:publicacoes.cespu.pt:article/51Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:50:22.025050Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
title |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
spellingShingle |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species Almeida-Santos, A. C. Selected Oral Communication |
title_short |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
title_full |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
title_fullStr |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
title_full_unstemmed |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
title_sort |
Novel insights into healthy humans’ faecal carriage of enterococci: Enterococcus lactis is as a dominant highly bacteriocinogenic species |
author |
Almeida-Santos, A. C. |
author_facet |
Almeida-Santos, A. C. Duarte, B. Teixeira, M. J. Tedim, A. P. Novais, C. Peixe, L. Freitas, A. R. |
author_role |
author |
author2 |
Duarte, B. Teixeira, M. J. Tedim, A. P. Novais, C. Peixe, L. Freitas, A. R. |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Almeida-Santos, A. C. Duarte, B. Teixeira, M. J. Tedim, A. P. Novais, C. Peixe, L. Freitas, A. R. |
dc.subject.por.fl_str_mv |
Selected Oral Communication |
topic |
Selected Oral Communication |
description |
Background: Enterococcus lactis (Elts) [former Enterococcus faecium (Efm) clade-B] has been greatly associated with human colonization, but its epidemiology is unknown since this reclassification [1]. We aimed to assess the contemporary faecal carriage of enterococci species among healthy-humans (HH) in Portugal and get novel insights about Efm/Elts differences. Methods: Fifty-one faecal samples (29-women/22-men;18-85/~45-years) from HH in Northern Portugal (February-July 2022) were processed by enrichment/selection steps with/without ampicillin, vancomycin or linezolid. Efm, Elts and other species were identified by PCR [2, 3] and antibiotic-susceptibility by disk-diffusion/broth-microdilution (EUCAST/CLSI). Representatives/sample (n=40) were characterized by Whole-Genome-Sequencing/CGE-tools, including a homemade bacteriocins(bac) database. Qualitative bacteriocin production/sensitivity was performed in sequenced Efm/Elts and selected clinical VREfm (vancomycin-resistant-Efm) and Elts (all-against-all) using the soft-agar-overlay technique. Results: All samples carried Enterococcus (n=337), with most containing Elts-73% (p<0.05) and/or E.faecalis (Efs)-61% and variable occurrence for Efm-45%, E.hirae-16%, and/or other species (<2%). Samples (24% multidrug-resistant) included isolates resistant to erythromycin [73%;erm(B)/msr(C)], tetracycline [63%;tet(M)/tet(L)], high-level-streptomycin (22%;ant(6)-Ia/str), chloramphenicol (12%;cat/fexA/fexB/optrA/poxtA), quinupristin-dalfopristin (12%), high-level-gentamycin [4%;aac(6’)-Ie-aph(2’’)-Ia] and linezolid (4%-optrA/poxtA;MIC50/MIC90 4-mg/L). Acquired linezolid-resistance genes were detected in two samples: optrA (one E. thailandicus; MIC=8-mg/L) and optrA+poxtA (ST128-Efm; MIC=8-16-mg/L). Typical bacteriocins and plasmids from clinical Efm/Efs were scarce. Elts (2-5 bac; 100%-bac-genes+) and Efm (0-9; 71%-bac+) shared bacteriocins (e.g.,entP/entQ) contrasting with others exclusive of Efs (0-2;22%-bac+). No isolate could inhibit all or be inhibited by all, but the ones with more bacteriocins were less inhibited. Most Efm/Elts showed no activity against each other but ~30%/each inhibited most strains tested, including VREfm. Conclusions: Elts is one predominant enterococci gut species that would be misidentified as Efm without an accurate Efm/Elts distinction. Elts co-exist with Efm in the intestine, but specific Efm/Elts inhibiting most strains tested may contribute to microbiota restoration after antibiotic treatments. Linezolid-resistance genes finding is worrisome, suggesting an environmental/food-chain role in this acquisition since they were not described in enterococci from Portuguese hospitals before. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-04-21 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.48797/sl.2023.51 https://doi.org/10.48797/sl.2023.51 |
url |
https://doi.org/10.48797/sl.2023.51 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://publicacoes.cespu.pt/index.php/sl/article/view/51 https://publicacoes.cespu.pt/index.php/sl/article/view/51/104 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
IUCS-CESPU Publishing |
publisher.none.fl_str_mv |
IUCS-CESPU Publishing |
dc.source.none.fl_str_mv |
Scientific Letters; Vol. 1 No. Sup 1 (2023) 2795-5117 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131583702106112 |